For some medical conditions there are hundreds of bacteria shifts reported, for others only a few. The Percentage is based on the least number. If there are matches 8 matches for a condition that has 10 known bacteria shifts, against a condition that has 50 bacteria shifts. It will be 8/10 or 80% and not 8/50= 16%. The count of possible bacteria is shown for reference.
Limited to conditions with 5 or more bacteria
Name | Overlap Percent | Prevalance in Population | Matches | Bacteria in From | Bacteria in To |
---|---|---|---|---|---|
Allergies | 22 % | 30% | 11 | 50 | 100 |
Alzheimer's disease | 46 % | 10% | 23 | 50 | 100 |
Autism | 31 % | 2% | 31 | 110 | 100 |
Ulcerative colitis | 25 % | 0.1% | 25 | 108 | 100 |
Rosacea | 40.9 % | 5.46% | 9 | 22 | 100 |
Schizophrenia | 30.1 % | 0.75% | 28 | 93 | 100 |
Ankylosing spondylitis | 35 % | 7% | 35 | 520 | 100 |
Mood Disorders | 50 % | 29.7% | 3 | 6 | 100 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 32 % | 0.86% | 32 | 134 | 100 |
Psoriasis | 34.8 % | 3% | 16 | 46 | 100 |
Obesity | 27.3 % | 42.4% | 15 | 55 | 100 |
Obesity | 18 % | 42.4% | 18 | 104 | 100 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 23.3 % | 0.005% | 10 | 43 | 100 |
Osteoporosis | 27.3 % | 9.4% | 6 | 22 | 100 |
neuropsychiatric disorders (PANDAS, PANS) | 33.3 % | 0.1% | 5 | 15 | 100 |
ME/CFS with IBS | 26.3 % | 2.8% | 5 | 19 | 100 |
ME/CFS without IBS | 23.1 % | 0.4% | 6 | 26 | 100 |
Multiple system atrophy (MSA) | 38.1 % | 0.005% | 8 | 21 | 100 |
Metabolic Syndrome | 28.6 % | 21% | 2 | 7 | 100 |
Systemic Lupus Erythematosus | 27.3 % | 0.15% | 18 | 66 | 100 |
Liver Cirrhosis | 48 % | 0.27% | 48 | 678 | 100 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 19.7 % | 25% | 15 | 76 | 100 |
Parkinson's Disease | 28.9 % | 1% | 26 | 90 | 100 |
Chronic Kidney Disease | 31.4 % | 15% | 11 | 35 | 100 |
Insomnia | 70 % | 30% | 7 | 10 | 100 |
Depression | 23.5 % | 8% | 19 | 81 | 100 |
Irritable Bowel Syndrome | 32.3 % | 15% | 20 | 62 | 100 |
Chronic Urticaria (Hives) | 47.8 % | 5% | 11 | 23 | 100 |
IgA nephropathy (IgAN) | 24.1 % | 0.001% | 7 | 29 | 100 |
Hyperlipidemia (High Blood Fats) | 36 % | 33% | 9 | 25 | 100 |
hypertension (High Blood Pressure | 50 % | 47% | 3 | 6 | 100 |
hypercholesterolemia (High Cholesterol) | 22.2 % | 12% | 2 | 9 | 100 |
gallstone disease (gsd) | 33.3 % | 5% | 5 | 15 | 100 |
Graves' disease | 25 % | 0.5% | 2 | 8 | 100 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 29.2 % | 27.8% | 7 | 24 | 100 |
Fibromyalgia | 35.1 % | 1.12% | 13 | 37 | 100 |
Functional constipation / chronic idiopathic constipation | 39 % | 14% | 16 | 41 | 100 |
Epilepsy | 32 % | 0.84% | 8 | 25 | 100 |
Cerebral Palsy | 58.8 % | 0.2% | 10 | 17 | 100 |
Inflammatory Bowel Disease | 33.3 % | 1.3% | 22 | 66 | 100 |
Type 1 Diabetes | 30.8 % | 0.19% | 16 | 52 | 100 |
cystic fibrosis | 28.6 % | 0.03% | 2 | 7 | 100 |
COVID-19 | 22.2 % | 50% | 8 | 36 | 100 |
Carcinoma | 31.4 % | 1% | 16 | 51 | 100 |
Colorectal Cancer | 24 % | 4.3% | 24 | 296 | 100 |
Celiac Disease | 19.4 % | 1.4% | 13 | 67 | 100 |
Chronic Fatigue Syndrome | 21.8 % | 3% | 12 | 55 | 100 |
Crohn's Disease | 36 % | 0.3% | 36 | 141 | 100 |
Coronary artery disease | 12.5 % | 6.7% | 2 | 16 | 100 |
Barrett esophagus cancer | 18.8 % | 7% | 3 | 16 | 100 |
Generalized anxiety disorder | 14.3 % | 2.7% | 2 | 14 | 100 |
Bipolar Disorder | 36.4 % | 3% | 12 | 33 | 100 |
Asthma | 37 % | 8% | 10 | 27 | 100 |
Atherosclerosis | 37 % | 50% | 37 | 524 | 100 |
Acne | 42.1 % | 47% | 8 | 19 | 100 |
Stress / posttraumatic stress disorder | 28.6 % | 5.2% | 16 | 56 | 100 |
Small Intestinal Bacterial Overgrowth (SIBO) | 25 % | 52% | 4 | 16 | 100 |
Brain Trauma | 36.4 % | 0.367% | 8 | 22 | 100 |
Sjögren syndrome | 29.3 % | 1.2% | 12 | 41 | 100 |
Type 2 Diabetes | 51 % | 10.8% | 51 | 267 | 100 |
ADHD | 38.3 % | 9.4% | 18 | 47 | 100 |
Hashimoto's thyroiditis | 35.7 % | 0.35% | 5 | 14 | 100 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 ยงโฏ1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.